Key result
Tislelizumab triggers severe myasthenia gravis and acute coronary syndrome with persistently elevated troponin.
Why the study?
PD-1 inhibitors can cause serious immune-related adverse events including myasthenia gravis and myocardial injury, complicating diagnosis and management.
Case Report (n=1)
No
Persistently elevated hs-TnT following the resolution of neurological symptoms in PD-1 inhibitor-induced myasthenia gravis may signal ongoing coronary pathology and a high risk of future major adverse cardiac events.
Answers are grounded in this paper and cite their sources.
May signal ongoing coronary risk requiring vigilance after PD-1 inhibitor myasthenia gravis; leaves open whether troponin monitoring improves outcomes.
Background PD-1 inhibitors can cause serious immune-related adverse events, including myasthenia gravis (MG). The occurrence of myocardial injury during immune checkpoint inhibitor therapy can pose diagnostic challenges. Case presentation A 65-year-old man with hepatocellular carcinoma developed severe PD-1 inhibitor-associated MG after receiving tislelizumab. During the acute phase, he developed acute myocardial injury, with marked hs-cTnT elevation and new ST-segment depression on electrocardiography, and non-ST-segment elevation myocardial infarction (NSTEMI) was clinically suspected. His myasthenic symptoms gradually improved with immunosuppressive therapy, whereas hs-cTnT remained elevated during follow-up. Seven months after the initial presentation, he developed an ST-segment elevation myocardial infarction due to total occlusion of the proximal left anterior descending artery and underwent percutaneous coronary intervention. Conclusion This case highlights the need to carefully evaluate the underlying cause of myocardial injury in patients with severe PD-1 inhibitor-associated MG. Persistent hs-cTnT may identify patients at increased cardiovascular risk, although the prognostic significance of this finding requires further investigation.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2026) conducted a case report in Hepatocellular carcinoma, PD-1 inhibitor-induced myasthenia gravis, acute coronary syndrome (n=1). Tislelizumab was evaluated. Tislelizumab therapy in a 65-year-old man with hepatocellular carcinoma induced severe myasthenia gravis and acute coronary syndrome accompanied by delayed and persistently elevated high-sensitivity troponin T.
Synapse has enriched 10 related papers. Consider them for comparative context: